tiprankstipranks
MEI Pharma downgraded to Neutral from Buy at BTIG
The Fly

MEI Pharma downgraded to Neutral from Buy at BTIG

BTIG analyst Justin Zelin downgraded MEI Pharma to Neutral from Buy without a price target. The company announced plans to initiate strategic realignment of its portfolio following feedback with partner Kyowa Kirin from the FDA at a late November Meeting, where the parties will discontinue global development of Zandelisib, Zelin tells investors in a research note. The analyst downgrades MEI saying the primary valuation driver was future revenues from Zandelisib. He now awaits further clinical updates from the company’s early-stage pipeline assets next year.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MEIP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles